Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 222Carcinoma, Non-Small-Cell Lung 219Prostatic Neoplasms 156Multiple Myeloma 142Neoplasms 133Colorectal Neoplasms 118Leukemia, Myeloid, Acute 110Lung Neoplasms 103Neoplasm Metastasis 96Squamous Cell Carcinoma of Head and Neck 91Carcinoma, Hepatocellular 86Lymphoma 81Melanoma 78Pancreatic Neoplasms 74Triple Negative Breast Neoplasms 72Ovarian Neoplasms 66Sarcoma 65Lymphoma, Large B-Cell, Diffuse 61Carcinoma, Renal Cell 61Brain Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Head and Neck Neoplasms 57Recurrence 56Lymphoma, Non-Hodgkin 55Stomach Neoplasms 53Leukemia, Lymphocytic, Chronic, B-Cell 52Hematologic Neoplasms 52Endometrial Neoplasms 50Small Cell Lung Carcinoma 48Urinary Bladder Neoplasms 46

Interventions

spartalizumab 1pembrolizumab 1Radiosurgery 1Oncolytic Virotherapy 1Leucovorin 1Irinotecan 1IFL protocol 1Fluorouracil 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × CRC × 90 days × Clear all
NCT07381309 2026-04-28

VVSHIP

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Not yet recruiting
114 enrolled
Gastrointestinal

CRC

NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 2 Withdrawn

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡